These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20515438)

  • 1. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
    Aspenberg P; Schilcher J; Fahlgren A
    Acta Orthop; 2010 Aug; 81(4):460-2. PubMed ID: 20515438
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report.
    Puah KL; Tan MH
    Acta Orthop; 2011 Jun; 82(3):380-2. PubMed ID: 21561306
    [No Abstract]   [Full Text] [Related]  

  • 3. Femoral canal obliteration secondary to prolonged alendronate use: a case report.
    Lim CT; Setiobudi T; Das De S
    J Orthop Surg (Hong Kong); 2012 Apr; 20(1):115-7. PubMed ID: 22535826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biphosphonate treatment can cause stress fracture. But treatment benefits significantly overweight the risk].
    Sjödén G; Sayed-Noor A; Kadum B; Pettersson U
    Lakartidningen; 2010 Oct 13-19; 107(41):2482-3. PubMed ID: 21137565
    [No Abstract]   [Full Text] [Related]  

  • 5. A rational approach to management of alendronate-related subtrochanteric fractures.
    Das De S; Setiobudi T; Shen L; Das De S
    J Bone Joint Surg Br; 2010 May; 92(5):679-86. PubMed ID: 20436006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series.
    Bögl HP; Aspenberg P; Schilcher J
    Osteoporos Int; 2017 Aug; 28(8):2439-2444. PubMed ID: 28474166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
    Osugi K; Miwa S; Marukawa S; Marukawa K; Kawaguchi Y; Nakato S
    Acta Orthop; 2011 Feb; 82(1):112-3. PubMed ID: 21142824
    [No Abstract]   [Full Text] [Related]  

  • 8. Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
    Wang K; Moaveni A; Dowrick A; Liew S
    J Orthop Surg (Hong Kong); 2011 Apr; 19(1):89-92. PubMed ID: 21519086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.
    Cermak K; Shumelinsky F; Alexiou J; Gebhart MJ
    Clin Orthop Relat Res; 2010 Jul; 468(7):1991-6. PubMed ID: 20020334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?
    Ha YC; Cho MR; Park KH; Kim SY; Koo KH
    Clin Orthop Relat Res; 2010 Dec; 468(12):3393-8. PubMed ID: 20865463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obliteration of the medullary canal in an atypical bisphosphonate-related femoral fracture.
    Cawley DT; Barrett HL; Harrington P
    BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25568263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?
    Edwards MH; McCrae FC; Young-Min SA
    Osteoporos Int; 2010 Apr; 21(4):701-3. PubMed ID: 19562241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical femoral fractures bilaterally in a patient receiving denosumab.
    Drampalos E; Skarpas G; Barbounakis N; Michos I
    Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
    [No Abstract]   [Full Text] [Related]  

  • 14. Femoral fractures in osteoporotic patients on bisphosphonates. A case report.
    Alshahrani F; Kendler D
    J Clin Densitom; 2012; 15(3):380-4. PubMed ID: 22572530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Femoral insufficiency fractures with bisphosphonate therapy. Cases study.
    Boszczyk A; Kowalski D; Zakrzewski P; Pomianowski S
    Ortop Traumatol Rehabil; 2011; 13(4):403-8. PubMed ID: 21857071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
    Angthong C; Angthong W
    J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenesis of atypical femoral fracture].
    Iwata K; Mashiba T
    Clin Calcium; 2016 Jan; 26(1):73-9. PubMed ID: 26728533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature.
    Agarwal S; Agarwal S; Gupta P; Agarwal PK; Agarwal G; Bansal A
    Acta Orthop Belg; 2010 Oct; 76(5):567-71. PubMed ID: 21138208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-traumatic Atypical Peri-implant Femoral Fracture at the Distal Screw after Short Femoral Nail Fixation for a Pertrochanteric Fracture.
    Yamamoto N; Dan'ura T; Noda T; Ozaki T
    Acta Med Okayama; 2020 Apr; 74(2):151-157. PubMed ID: 32341590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture.
    O'Neill BJ; O'hEireamhoin S; Morrissey DI; Keogh P
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24700046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.